Company Sarepta Therapeutics, Inc. Sao Paulo
Equities
S1RP34
BRS1RPBDR005
Biotechnology & Medical Research
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
32.37 BRL | -0.28% |
|
-2.44% | +40.98% |
Jun. 13 | Health Care Flat on Mixed Drug Developments - Health Care Roundup | DJ |
Jun. 03 | Sarepta Therapeutics, Inc.(NasdaqGS:SRPT) added to S&P 1000 | CI |
Business Summary
Number of employees: 1,314
Sales per Business
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
RNA-targeted Therapeutics, Gene Therapy and Other Genetic Therapeutic Modalities
100.0
%
| 933 | 100.0 % | 1,243 | 100.0 % | +33.26% |
Sales per region
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
United States
100.0
%
| 933 | 100.0 % | 1,243 | 100.0 % | +33.26% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Douglas Ingram
CEO | Chief Executive Officer | 61 | 17-06-25 |
Ian Estepan
DFI | Director of Finance/CFO | 48 | 14-12-31 |
Bilal Arif
CTO | Chief Tech/Sci/R&D Officer | - | - |
Chief Tech/Sci/R&D Officer | 48 | 18-05-31 | |
Will Tilton
HRO | Human Resources Officer | - | - |
Alison Nasisi
HRO | Human Resources Officer | - | - |
Dallan Murray
PRN | Corporate Officer/Principal | - | 12-12-31 |
Diane Berry
PRN | Corporate Officer/Principal | - | 11-11-30 |
Ryan Brown
LAW | General Counsel | 46 | 17-12-31 |
Joseph Bratica
AUD | Comptroller/Controller/Auditor | 60 | 17-02-28 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Douglas Ingram
CEO | Chief Executive Officer | 61 | 17-06-25 |
M. Wilsey
CHM | Chairman | 71 | 09-03-30 |
Richard Barry
BRD | Director/Board Member | 65 | 15-06-01 |
Director/Board Member | 86 | 10-05-31 | |
Stephen Mayo
BRD | Director/Board Member | 62 | 21-11-15 |
Claude Nicaise
BRD | Director/Board Member | 71 | 15-06-01 |
Michael Chambers
BRD | Director/Board Member | - | 22-06-01 |
Kathryn Boor
BRD | Director/Board Member | 65 | 22-06-01 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 94,523,766 | 89,825,408 ( 95.03 %) | 0 | 95.03 % |
Company contact information
Sarepta Therapeutics, Inc.
215 First Street Suite 415
02142, Cambridge
+617 274 4000
http://www.sareptatherapeutics.com![address Sarepta Therapeutics, Inc.(S1RP34)](https://cdn.zonebourse.com/static/address/119084116.png)
Sector
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+14.84% | 121B | |
+18.31% | 112B | |
+2.94% | 22.72B | |
-18.26% | 20.82B | |
-18.47% | 16.66B | |
-42.36% | 16.36B | |
-14.23% | 16.19B | |
-0.68% | 13.17B | |
+111.62% | 10.57B |
- Stock Market
- Equities
- SRPT Stock
- S1RP34 Stock
- Company Sarepta Therapeutics, Inc.